New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For SPPI;TSLA;CROX;OMX;ANF From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
June 25, 2015
07:12 EDTTSLAAfter surveying 145 car owners, Jefferies raises Tesla price target
Jefferies analyst Dan Dolev raised his price target for Tesla shares to $360 from $350 after surveying 145 owners of the company's electric cars. The stock closed yesterday down $2.50 to $265.17. On average, owners were willing to pay 60% more for a Tesla, which suggests a much larger total addressable market when the lower priced Model III is introduced in 2017, Dolev tells investors this morning in a research note. Further, the survey highlighted "exceptional" brand loyalty, with 85% noting that their next car would be a Tesla, the analyst writes. Dolev upped his 2020 production estimate from 515K cars from 500K and keeps a Buy rating on Tesla.
06:00 EDTTSLATesla implied volatility of 29 at lower end of index mean range
Subscribe for More Information
June 24, 2015
09:35 EDTTSLAActive equity options trading on open
Subscribe for More Information
07:02 EDTSPPISpectrum announces publication of Beleodaq data in Journal of Clinical Oncology
Spectrum Pharmaceuticals announced the publication of results from the pivotal BELIEF -- CLN-19 -- Study, which was selected as a Rapid Communication in the Journal of Clinical Oncology, the journal of the American Society of Clinical Oncology. The study, led by Dr. Owen OíConnor from the Center for Lymphoid Malignancies, Department of Medicine, Columbia University Medical Center, New York, NY, showed that monotherapy with Beleodaq produced complete and durable responses with manageable toxicity in patients with R/R PTCL across the major subtypes, irrespective of the number or type of prior therapies. Beleodaq, previously known as belinostat, is a histone deacetylase inhibitor indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. This indication is approved under accelerated approval based on tumor Response Rate and Duration of Response. An improvement in survival or disease-related symptoms has not been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial. The primary endpoint of the BELIEF study was ORR as assessed centrally by an Independent Review Committee using the International Working Group criteria. The ORR in the 120 evaluable patients was 25.8%, including 13 Complete Responses and 18 Partial Responses. Secondary endpoints included a median DoR of 13.6 months by IWG criteria and 8.4 months to disease progression or death, with the longest ongoing patient at ≥36 months. The most common Grade 3/4 adverse events were anemia, thrombocytopenia, dyspnea, and neutropenia. No clinically relevant ECG changes were identified, and cardiovascular monitoring of ECGs is not required at baseline or during treatment. In this pivotal study, monotherapy with Beleodaq produced complete and durable responses with manageable toxicity in patients with R/R PTCL across the major disease subtypes, irrespective of the number or type of prior therapies and with a low incidence of Grade 3/4 thrombocytopenia.
June 23, 2015
11:39 EDTTSLAStocks with call strike movement; TSLA MU
Subscribe for More Information
07:36 EDTANFJMP Securities to hold a conference
Subscribe for More Information
June 22, 2015
16:00 EDTTSLAOptions Update; June 22, 2015
iPath S&P 500 VIX Short-Term Futures down 78c to 17.45. Option volume leaders: AAPL FB BAC CHK WMB BABA TWTR MU AMBA TSLA JPM
12:18 EDTTSLATesla volatility low after saying Model 3 'remains on schedule'
Subscribe for More Information
11:33 EDTTSLATesla off lows after saying Model 3 'remains on schedule'
Shares of Tesla are off their lows after the company told Bloomberg that production of the $35,000 Model 3 "remains on schedule." The comment comes after website Inside EVs reported yesterday that production of the lower priced model was pushed back to 2018. The Model 3 will reach full production in 2018, but production will start in 2017, the electric car maker told Bloomberg in an emailed statement. Shares of Tesla are down $2.51 to $260.00 in morning trading. The stock fell as low as $255.69 today.
11:17 EDTTSLATesla spokesperson says Model 3 'on schedule,' Bloomberg reports
Subscribe for More Information
10:06 EDTTSLATesla delays Model 3 launch to 2018, InsideEVs reports
Subscribe for More Information
09:48 EDTTSLATesla's need for cash and high stock price may be risky, WSJ reports
Tesla may be raising more money while it can after taking out a revolving credit agreement with several major banks, reports the Wall Street Journal. Current Finance Chief Deepak Ahuja's successor will likely make use of the new funding as the company's CapEx have often outpaced its operating cash flow. But if the Model X launch stumbles, the cash burn could exceed $1.5B and may end 2015 with less than $1B in available liquidity in a gloomier scenario. Reference Link
June 19, 2015
07:50 EDTTSLATesla wins $15M tax break from California, L.A. Times reports
Tesla Motors has won a $15M tax break from the state of California, the L.A. Times reports. The California Governorís Office of Business and Economic Development voted to include the auto maker among more than 60 companies that will share in an almost $50M tax break package, the report says. Tesla said it will use the money to add over 4,000 new jobs to its Bay Area factories and plants, enough jobs to make it the largest manufacturing employer in the state of California, the L.A. Times says. Reference Link
June 18, 2015
12:04 EDTTSLAActive options: AAPL ORCL FB RAD BAC HTZ MU GE TSLA AMZN BABA KO
Subscribe for More Information
09:35 EDTTSLAActive equity options trading on open
Subscribe for More Information
June 17, 2015
14:42 EDTTSLAOption volume leaders
Subscribe for More Information
11:34 EDTTSLATesla enlists leading battery researcher to drive down costs, WSJ says
Subscribe for More Information
10:36 EDTTSLATesla spikes on Ron Barron comments on CNBC
Subscribe for More Information
07:30 EDTTSLABaron sees 'huge opportunity' in Tesla
Ron Baron said while speaking on CNBC that he "loves Tesla" and sees a huge opportunity for the company and the stock. Baron said he expects to make 10 to 20 times his money in 20 years via his investment in Tesla stock.
June 16, 2015
06:59 EDTTSLATesla management to meet with FBR Capital
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use